Ethical Rationale for the Ebola “Ring Vaccination” Trial Design
- 1 March 2016
- journal article
- Published by American Public Health Association in American Journal of Public Health
- Vol. 106 (3), 432-435
- https://doi.org/10.2105/ajph.2015.302996
Abstract
The 2014 Ebola virus epidemic is the largest and most severe ever recorded. With no approved vaccines or specific treatments for Ebola, clinical trials were launched within months of the epidemic in an unprecedented show of global partnership. One of these trials used a highly innovative “ring vaccination” design. The design was chosen for operational, scientific, and ethical reasons—in particular, it was regarded as ethically superior to individually randomized placebo-controlled trials. We scrutinize the ethical rationale for the ring vaccination design. We argue that the ring vaccination design is ethical but fundamentally equivalent to placebo-controlled designs with respect to withholding a potentially effective intervention from the control group. We discuss the implications for the ongoing ring vaccination trial and future research.Keywords
This publication has 17 references indexed in Scilit:
- A Recombinant Vesicular Stomatitis Virus Ebola VaccineNew England Journal of Medicine, 2017
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialThe Lancet, 2015
- Interim results from a phase 3 Ebola vaccine study in GuineaThe Lancet, 2015
- Ebola vaccine trial in GuineaThe Lancet, 2015
- Ebola vaccine trial in west Africa faces criticismThe Lancet, 2015
- Ebola and beyondScience, 2015
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Bench to Bedside: Mapping the Moral Terrain of Clinical ResearchHastings Center Report, 2008
- The Therapeutic Orientation to Clinical TrialsNew England Journal of Medicine, 2003
- What Makes Clinical Research Ethical?JAMA, 2000